Inflammation is a complex, multicausal event that has been intimately linked to the progression of a broad range of acute and chronic diseases. Current treatments for inflammation-driven disease are either systemic, which often cause adverse effects, or are only capable of treating just one or a few causal factors of inflammation, making them sub-optimal. Vyome Therapeutics is working to treat inflammatory diseases using locally-acting, next generation therapeutic solutions with validated novel mechanisms of action and effective formulations for site-targeted applications. Vyome’s platform strategy is to develop safer and more effective alternatives to standards of care in multifactorial diseases of high unmet need which are underpinned by inflammation.
Acne is caused by a bacteria, Cutibacterium acne (C. acnes). Over 240 million patients suffer from mild to moderate acne globally and are treated with antibiotics. Over 100 million of these patients are resistant to current topical antibiotics used to treat acne, and are forced to take oral systemic acne treatments, which are associated with risk of adverse events. Even when effective in killing C. acnes infections, most antibacterial treatments are incapable of eliminating the subsequent immune response which causes local inflammation.
Vyome is working to create a solution for resistant inflammatory acne by developing VB-1953, a DNA Gyrase/Topoisomerase IV and MD2-TLR inhibitor, which has been shown to have a powerful bactericidal effect in addition to blocking inflammatory cytokine production. This novel dual bactericidal and anti-inflammatory mechanism can be leveraged to treat acne caused by antibiotic-resistant C. acnes bacterial strains, an unmet medical need affecting one in three acne patients in the US. VB-1953's multifaceted therapeutic effect could allow for a safe and effective topical alternative to oral, systemic drugs in inflammatory acne. Vyome merges this next-generation small molecule with an IP-protected microtechnology gel system that allows VB-1953 to be locally administered, and ensures the drug is retained at the site of infection and minimizes systemic exposure.
Noninfectious uveitis is a serious inflammatory condition of the eye caused by aberrant immune cell activity in the uvea. The disease is estimated to affect more than 300,000 American adults and children each year and if left untreated, it can lead to vision loss. The current standard of care for noninfectious uveitis is treatment with steroids, either given locally through an eye drop or systemically in a shot or pill. With steroid treatment having potential serious side effects including increasing intraocular pressure, a better locally acting treatment option could significantly improve the current treatment paradigm for this disease.
Vyome is developing VT-1908 as an alternative treatment option for immune cell-mediated noninfectious uveitis. VT-1908 is a preclinical stage inosine-5'-monophosphate dehydrogenase inhibitor being developed as a locally-administered treatment option. Preclinically, VT-1908 has shown the ability to reduce inflammation in the uvea through the inhibition of aberrant B and T cell activity, and could potentially treat uveitis without the need for steroids, local or systemic.
Otitis media is a condition of the middle ear caused by a viral or bacterial infection which leads to inflammation behind the ear drum. If not resolved, complications can occur including hearing loss and ear drum rupture. It is estimated that about 80% of children globally will experience at least one case of otitis media in their lifetime. The goal of treatment is to control pain due to inflammation and target the infection, but there is no current treatment that can address both the inflammation and infection simultaneously.
Vyome is developing VT-1917 for the treatment of otitis media. VT-1917 is a preclinical stage dual DNA Gyrase/Topoisomerase IV and a MD2-TLR inhibitor which has been optimized for local ear administration. The dual bactericidal and anti-inflammatory effect differentiates VT-1917 from the current standard of care.
As a therapeutic area, the anti-fungal space has suffered from a lack of innovation for decades. Doctors & patients are dissatisfied with the current treatment options and there are multiple unmet needs. Vyome's anti-fungal platform technology for treatment of recalcitrant fungal infections has aided in development of novel anti-fungal products with enhanced efficacy over existing leading brands, as envisaged in the in vitro & in vivo studies performed by Vyome. Vyome has developed treatment options for Tinea & Candida fungi species.
For partnership queries, visit Partnering Opportunities.
Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.